Perspectives on Prostate Cancer Biomarkers

European Urology

Volumn 54, Issue 1, 2008, Pages 8-10

  Shariat, Shahrokh F ^a   Karakiewicz, Pierre I ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

CLINICAL PRACTICE; EDITORIAL; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 44149085674     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.074     Document Type: Editorial

References (11)

1. Steuber T., O'Brien M.F., and Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 54 (2008) 31-40
2. Gutman S., and Hackett J. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side. Pharmacogenomics 7 (2006) 1223-1227
3. van Gils M.P.M.Q., Stenman U.H., Schalken J.A., et al. Innovations in serum and urine markers in prostate cancer: current European research in the P-Mark project. Eur Urol 48 (2005) 1031-1041
4. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
5. Bensalah K., Montorsi F., and Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 52 (2007) 1601-1609
6. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21 (2003) 3573-3579
7. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112 (2008) 315-325
8. Srivastava S., and Rossi S.C. Early detection research program at the NCI. Int J Cancer 69 (1996) 35-37
9. Shariat S.F., Canto E.I., Kattan M.W., et al. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6 (2004) 58-72
10. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
11. Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136